gms | German Medical Science

65th Annual Meeting of the German Society of Neurosurgery (DGNC)

German Society of Neurosurgery (DGNC)

11 - 14 May 2014, Dresden

Nucleocytoplasmatic shuttling receptors: novel biomarkers for meningiomas recurrence

Meeting Abstract

Search Medline for

  • Konstantinos Gousias - Abteilung für Neurochirurgie, Universitätsklinikum Bonn
  • Pitt Niehusmann - Institut für Neuropathologie, Universitätsklinikum Bonn
  • Matthias Simon - Abteilung für Neurochirurgie, Universitätsklinikum Bonn

Deutsche Gesellschaft für Neurochirurgie. 65. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC). Dresden, 11.-14.05.2014. Düsseldorf: German Medical Science GMS Publishing House; 2014. DocDI.10.02

doi: 10.3205/14dgnc169, urn:nbn:de:0183-14dgnc1693

Published: May 13, 2014

© 2014 Gousias et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: Expression levels of nucleocytoplasmic shuttling receptors (karyopherins) such as karyopherin a2 (KPNA2, importin) and chromosome region maintenance protein 1 (CRM1, exportin) have been found to correlate with a higher WHO grade and a poorer prognosis in patients with infiltrative astrocytomas. The aim of this study was to evaluate these karyopherins as novel biomarkers also for meningiomas of WHO grades I-III.

Method: Nuclear expression of KPNA2, CRM1 and the MIB1 labeling index were analyzed by immunohistochemistry in 108 primary (44 meningiomas WHO grade I, 47 atypical meningiomas WHO grade II, 17 anaplastic meningiomas WHO grade III) and 13 recurrent meningiomas. Statistical analysis was performed using standard techniques.

Results: KPNA2 (p<0.001) and CRM1 (p=0.002) expression levels correlated significantly with the histological grade. KPNA2 expression correlated with proliferative activity as assessed by the MIB1 index (p<0.001). Recurrent tumors expressed significantly higher levels of KPNA2 (p=0.045) when compared to primary growths. A multivariate Cox regression analysis with sex, age, preoperative and postoperative KPS, degree of resection, histology, administration of radiotherapy, preoperative presence of neurological deficit, tumor location, tumor size as well as KPNA2 and CRM1 immunostaining and the MIB1 labeling index as covariables identified higher KPNA2 and CRM1 expression levels as independent predictors of tumor recurrence in the overall series as well as in patients with atypical meningiomas.

Conclusions: KPNA2 and CRM1 expression may have potential as novel biomarkers for meningiomas.